Brivaracetam (BRV) is the latest anti-epileptic drug (AED) approved for adjunctive therapy of focal onset seizures and was introduced to the German market in February 2016. Similarly to Levetiracetam (LEV), BRV acts through binding synaptic vesicle protein 2 A which plays a role in synaptic vesicle trafficking and is distributed almost ubiquitously in the central nervous system. Orally administered BRV is resorbed completely and quickly and is metabolized via cytochrome P450-dependent and -independent pathways with its metabolites being eliminated renally.
14
OCT
OCT
0